3,5-dimethoxytyramine

3,5-Dimethoxytyramine (4-O-Desmethylmescaline)

1. Identity and Chemical Characterization

Names and Classification

3,5-Dimethoxytyramine is a naturally occurring alkaloid belonging to the phenethylamine chemical class. It carries several synonymous chemical names in the scientific literature, reflecting its structural relationship to mescaline: it is formally designated 4-O-Desmethylmescaline, and is also recorded as 3,5-dimethoxy-4-hydroxyphenethylamine, 4-hydroxymescaline, and by the informal research designation DESMETHYL. 4-O-Desmethylmescaline, also known as 3,5-dimethoxy-4-hydroxyphenethylamine, 4-hydroxymescaline, 3,5-dimethoxytyramine, or DESMETHYL, is an alkaloid and drug of the phenethylamine and scaline families related to mescaline.

The compound belongs to the broader "scaline" subfamily of substituted phenethylamines — a group characterized by 3,5-dimethoxy substitution on the aromatic ring with varying substituents at the 4-position. It is the analogue of mescaline in which the methyl ether at the 4-position hydroxyl group has been removed. In other words, where mescaline (3,4,5-trimethoxyphenethylamine) bears three methoxy (–OCH₃) groups, 3,5-dimethoxytyramine has only two methoxy groups (at positions 3 and 5) with a free hydroxyl (–OH) group at position 4, giving it the characteristic tyramine-like hydroxyl that accounts for its "tyramine" suffix in nomenclature.

Structurally, the compound is closely related to the broader family of cactus phenethylamine alkaloids. Cactus alkaloids are found in the cactus family, particularly in the genus Lophophora, which alone contains over 40 known compounds. The alkaloids can be categorized into two groups, derived from phenethylamine and tetrahydroisoquinoline, respectively.

Additionally, 3,5-dimethoxytyramine has been identified in pharmacological research as a substrate of dopamine-β-hydroxylase, the enzyme responsible for converting dopamine to norepinephrine in the catecholamine biosynthetic pathway. The enzyme dopamine-β-oxidase not only effects the hydroxylation of dopamine to norepinephrine, but accepts as substrates a wide variety of phenethylamine derivatives such as epinine, m-tyramine and their branched α-methyl derivatives, m-methoxytyramine, which is converted to normetanephrine, 3,5-dimethoxytyramine, and to some extent even mescaline.

Common Forms and Preparations

3,5-Dimethoxytyramine does not currently appear as a stand-alone commercial dietary supplement ingredient in the mainstream market; it is instead encountered primarily as a minor constituent within crude preparations derived from mescaline-containing cacti, or as a reference standard in analytical and pharmacological research. Phenethylamines are found in many plant families throughout the plant kingdom, particularly rich in variously substituted phenethylamines are the families Cactaceae and Leguminosae. In research contexts, it is typically encountered as an analytically characterized isolate or synthetic reference standard. In traditional ethnobotanical use, it was consumed as part of the whole-plant alkaloid mixture of peyote buttons or cactus preparations, rather than in isolated form.

2. Natural Sources and Botanical Origin

3,5-Dimethoxytyramine occurs naturally in multiple species of cacti, as well as in certain leguminous plants. The compound occurs naturally in various cacti species, for instance those of the genera Lophophora, Trichocereus, Opuntia, and Stenocereus, among others. It also occurs in certain Acacia species. The primary sources in terms of historical and ethnopharmacological significance are the peyote cactus (Lophophora williamsii) and the San Pedro cactus (Echinopsis pachanoi, formerly Trichocereus pachanoi).

Lophophora williamsii (peyote): The peyote (Lophophora williamsii) is a small, spineless cactus which contains psychoactive alkaloids, particularly mescaline. "Peyote" is a Spanish word derived from the Nahuatl peyōtl, meaning "caterpillar cocoon." It is native to southern North America, primarily found in desert scrub and limestone-rich areas of northern Mexico and south Texas, particularly in the Chihuahuan Desert at elevations of 100–1,500 m. Peyote contains a large spectrum of phenethylamine alkaloids. The principal one is mescaline for which the content of Lophophora williamsii is about 0.4% fresh (undried) and 3–6% dried. 3,5-Dimethoxytyramine is present as a minor alkaloid within this complex alkaloid profile, which encompasses over 40 identified compounds. To date, over 40 different alkaloids have been isolated from the Lophophora genus. Of these, only the pharmacological actions of mescaline have been extensively investigated.

Echinopsis pachanoi (San Pedro cactus): Echinopsis pachanoi contains a number of alkaloids, including the well-studied chemical mescaline (from 0.053% up to 4.7% of dry cactus weight), and also 3,4-dimethoxyphenethylamine, 3-methoxytyramine, 4-hydroxy-3,5-dimethoxyphenethylamine, anhalonidine, anhalinine, hordenine, and tyramine. It is important to note that "4-hydroxy-3,5-dimethoxyphenethylamine" is the IUPAC systematic name for 3,5-dimethoxytyramine itself, confirming the compound's presence in this species.

Phenethylamines are found in many plant families throughout the plant kingdom, particularly rich in variously substituted phenethylamines being the families Cactaceae and Leguminosae. Most common among the natural phenethylamines are para-hydroxylated derivatives, tyramine, N-methyltyramine, and hordenine, and these compounds occur in most of the plant families.

3. Biosynthesis and Role as a Natural Intermediate

3,5-Dimethoxytyramine holds a significant place in the biosynthetic pathway of mescaline within the Cactaceae. 4-O-Desmethylmescaline may be a biosynthetic precursor of mescaline in cacti and is also known to be a minor metabolite of mescaline. This dual role — as both a precursor and a downstream metabolite — reflects the compound's position at a critical branch point in the plant's phenethylamine alkaloid chemistry.

The biosynthesis of cactus alkaloids starts from the amino acid tyrosine and proceeds initially via tyramine and dopamine. In peyote specifically, the plant is capable of producing large amounts of alkaloids with psychotropic activity, such as β-phenylethylamine (class I) or tetrahydroisoquinoline (class II), which are derived from the amino acid tyrosine. Work on the L. williamsii transcriptome and recombinant enzyme characterization has helped elucidate these steps. Conversion of l-tyrosine to tyramine is likely the first step in the formation of hordenine followed by di-N-methylation. Tetrahydroisoquinoline (THIQ) alkaloids and their N-methylated derivatives are likely formed from the mescaline pathway intermediates 3-methoxytyramine and 3-methoxy-4,5-dihydroxy-PEA, respectively.

O-methyltransferase enzymes, using S-adenosylmethionine (SAM) as a methyl donor, catalyze the sequential methylation steps that convert hydroxylated tyramine derivatives toward mescaline. Tyramine undergoes a series of methylation reactions in which methyl groups (–CH₃) are added to the hydroxyl groups (–OH) present in the benzene ring. These reactions are catalyzed by specific enzymes called methyltransferases and use the compound S-adenosylmethionine (SAM) as a methyl group donor. First methylation: 3-methoxytyramine is produced. Second methylation: N-methoxy-3,4-dimethoxytyramine is formed. Third methylation: Finally, 3,4,5-trimethoxyphenethylamine is obtained, which is the basic chemical structure of mescaline. 3,5-Dimethoxytyramine is positioned along a parallel or branching route in this sequence, representing a hydroxylated intermediate that retains the free 4-OH group that in mescaline is methylated. A 2023 study in The Plant Journal used biochemical assays with recombinant enzymes and engineered yeast strains to determine substrate specificity in peyote biosynthetic genes. Biochemical assays with recombinant enzymes or functional analyses performed by feeding putative precursors to engineered yeast strains expressing candidate peyote biosynthetic genes were used to determine substrate specificity, which served as the basis for pathway elucidation. Additionally, an N-methyltransferase displaying broad substrate specificity and leading to the production of N-methylated phenethylamine derivatives was identified, which could also function as an early step in the biosynthesis of tetrahydroisoquinoline alkaloids in peyote.

The compound also participates in mammalian biochemistry as a substrate for dopamine-β-hydroxylase (also termed dopamine-β-oxidase), the enzyme that hydroxylates the β-carbon of phenethylamine-class substrates. This enzyme accepts a wide variety of phenethylamine derivatives, including 3,5-dimethoxytyramine, which can thereby be converted into a corresponding β-hydroxylated product. The enzyme dopamine-β-oxidase not only effects the hydroxylation of dopamine to norepinephrine, but accepts as substrates a wide variety of phenethylamine derivatives, including 3,5-dimethoxytyramine, and to some extent even mescaline.

4. Traditional and Historical Use

3,5-Dimethoxytyramine has never been used in isolation in any traditional cultural context. Its historical relevance derives entirely from its co-occurrence within the alkaloid profile of mescaline-containing cacti — most centrally peyote — which have been used by indigenous peoples of North and Mesoamerica for millennia.

Peyote among indigenous peoples of North America: Archaeological evidence establishes peyote use going back at least five to six millennia. Two archaeological specimens of peyote buttons (dried tops of the cactus Lophophora williamsii) from the collection of the Witte Museum in San Antonio were subjected to radiocarbon dating and alkaloid analysis. The samples were presumably found in Shumla Cave No. 5 on the Rio Grande, Texas. Radiocarbon dating shows that the calibrated ¹⁴C age of the weighted mean of the two individual dated samples corresponds to the calendric time interval 3780–3660 BC (one sigma significance). Radiocarbon dating of peyote "buttons" recovered from archaeological sites in this region suggests that peyote has been used for religious sacraments by indigenous communities for at least 5700 years.

Among North American indigenous traditions, peyote and its full alkaloid complement — including 3,5-dimethoxytyramine as a trace component — were consumed primarily in ceremonial and healing contexts. For centuries, North American indigenous peoples have used mescaline as a medicine and as a part of a hallucinogenic religious sacrament. The ceremonial use of peyote alkaloids has masked and mythologized the potential use of peyote in modern medicine. For example, some of the illnesses treated with peyote by Mexican Natives are tuberculosis, pneumonia, scarlet fever, intestinal ills, diabetes, rheumatic pains, colds, grippe, fevers, and venereal diseases, which is why peyote is officially listed in the Mexican pharmacopoeia.

Traditional methods of preparation and consumption encompassed direct ingestion of the dried cactus crowns ("buttons"), preparation of teas, and grinding into powder. People can ingest mescaline in several ways. Eating the dried crowns of the peyote cactus, boiling the cactus to make tea, and taking capsules containing peyote or mescaline are all common ways. There are also synthetic forms of mescaline, which are generally available in the form of capsules. In these preparations, 3,5-dimethoxytyramine was present as part of the total alkaloid complex, not as a targeted constituent.

The religious significance of these practices persists among groups such as the Native American Church, for whom peyote is considered sacred by indigenous groups such as the Native American Church and the Huichol people.

San Pedro cactus in Andean traditions: Echinopsis pachanoi, which also contains 3,5-dimethoxytyramine within its alkaloid complement, is a psychedelic drug and entheogen, also found in some other species of the genus Echinopsis and the species Lophophora williamsii (peyote). Mescaline induces a psychedelic state comparable to those produced by LSD and psilocybin, but with unique characteristics. San Pedro has been used for millennia by Andean cultures in healing and divination ceremonies, with the full alkaloid mixture — including trace amounts of 3,5-dimethoxytyramine — consumed as part of these preparations.

5. Key Constituents, Chemical Context, and Active Compounds

Within any peyote or San Pedro preparation, 3,5-dimethoxytyramine is one of many minor alkaloids that accompany the major psychoactive constituent, mescaline. Understanding 3,5-dimethoxytyramine requires placing it in the context of this broader alkaloid profile.

Mescaline (3,4,5-trimethoxyphenethylamine) is the quantitatively dominant and pharmacologically best-characterized alkaloid in these preparations. Mescaline (3,4,5-trimethoxyphenethylamine), mainly found in the peyote cactus (Lophophora williamsii), is one of the oldest known hallucinogenic agents that influence human and animal behavior, but its psychoactive mechanisms remain poorly understood. Its pharmacodynamic mechanisms of action are primarily attributed to the interaction with the serotonergic 5-HT2A-C receptors, and therefore clinical effects are similar to those elicited by other psychoactive substances, such as lysergic acid diethylamide (LSD) and psilocybin, which include euphoria, hallucinations, depersonalization, and psychoses.

3,5-Dimethoxytyramine itself is structurally distinguished from mescaline by the presence of a free 4-hydroxyl group rather than a methoxy group at that position. Within the scaline chemical family, 3,4,5-trimethoxyphenethylamine (mescaline) is a psychedelic alkaloid found in peyote cactus. Related 4-alkoxy-3,5-dimethoxy-substituted phenethylamines (scalines) and amphetamines (3C-scalines) are reported to induce similarly potent psychedelic effects and are therefore potential novel therapeutics for psychedelic-assisted therapy. The structural relationship of 3,5-dimethoxytyramine to the scalines is direct: it serves as the unalkylated "base" 4-hydroxy scaffold from which other scalines are derived by O-alkylation at position 4.

Other minor alkaloids in peyote include pellotine (the second most abundant in L. williamsii and the dominant alkaloid in L. diffusa), anhalinine, hordenine, tyramine, and various tetrahydroisoquinoline derivatives. Peyote contains a large spectrum of phenylethylamine alkaloids, the principal being mescaline. Pellotine is the second most abundant alkaloid in Lophophora williamsii, but it is by far the most abundant alkaloid in the other Lophophora spp., accounting for 70–90% of its total alkaloid content. In those species, mescaline is present only in trace concentrations, not necessarily high enough to produce pharmacological effects following ingestion of the cactus.

6. Mechanisms of Action

No dedicated mechanistic studies of 3,5-dimethoxytyramine in isolation have been published at the level of peer-reviewed human or clinical pharmacology as of the available literature. What is known derives from: (1) its structural relationship to mescaline and the scalines, (2) its enzymatic interactions, and (3) general knowledge about the pharmacology of related 3,5-dimethoxyphenethylamines at monoaminergic receptors.

Serotonin Receptor Interactions (Inferred from Structural Class)

The scaline family to which 3,5-dimethoxytyramine belongs has been studied in receptor binding assays. Several pharmacologically uninvestigated scalines and 3C-scalines were examined at key monoamine targets in vitro. Binding affinity at human serotonergic 5-HT₁A, 5-HT₂A, and 5-HT₂C, adrenergic α₁A and α₂A, and dopaminergic D₂ receptors, rat and mouse trace amine-associated receptor 1 (TAAR1), and human monoamine transporters were assessed using target-specific transfected cells. Generally, scalines and 3C-scalines bound with weak to moderately high affinity to the 5-HT₂A receptor (Kᵢ = 150–12,000 nM). It is not established from peer-reviewed sources what the specific binding affinity of 3,5-dimethoxytyramine itself is at 5-HT₂A or other receptors; the available scaline data pertains to 4-alkoxy derivatives rather than the 4-hydroxy compound.

Dopamine-β-Hydroxylase as a Metabolic Target

As noted in a foundational biochemical study, 3,5-dimethoxytyramine is recognized as a substrate by dopamine-β-hydroxylase (dopamine-β-oxidase), the enzyme that catalyzes β-hydroxylation of phenethylamine substrates. The enzyme dopamine-β-oxidase accepts as substrates a wide variety of phenethylamine derivatives, including 3,5-dimethoxytyramine. This means that, in mammalian tissues containing this enzyme (notably adrenal medulla and noradrenergic neurons), 3,5-dimethoxytyramine could theoretically be hydroxylated to a β-hydroxy derivative, though the pharmacological significance of this conversion in vivo has not been characterized in peer-reviewed human studies.

Trace Amine–Associated Receptor (TAAR1) Context

Many substituted phenethylamines interact with the trace amine-associated receptor 1 (TAAR1), a G protein-coupled receptor expressed in dopaminergic and serotonergic brain regions. TAAR1 is a G protein-coupled receptor (GPCR) that indirectly modulates monoaminergic neurotransmission by affecting dopaminergic, serotonergic, and noradrenergic tone. Whether 3,5-dimethoxytyramine is a functional TAAR1 ligand has not been established in peer-reviewed studies as a discrete experimental finding; this remains speculative based on structural analogy.

7. Scientific Evidence by Area

7.1 Evidence Directly Concerning 3,5-Dimethoxytyramine

The direct scientific evidence for 3,5-dimethoxytyramine as an isolated pharmacological agent is extremely limited. No registered clinical trials, systematic reviews, randomized controlled trials, or well-powered observational studies have been identified that specifically and exclusively examine 3,5-dimethoxytyramine in human subjects. The compound appears primarily in the literature as:

• A chemical entity identified in cactus alkaloid surveys (analytical chemistry studies using GC-MS, HPLC, and related techniques).
• A biosynthetic pathway intermediate in the mescaline biosynthetic pathway, studied in plant biochemistry and transcriptomics research.
• A substrate for mammalian enzymes (dopamine-β-hydroxylase), identified in early enzyme substrate studies.
• A reference compound in studies of mescaline derivatives and structural analogue series (scalines).

Evidence strength: Preclinical/analytical only. No clinical evidence for any specific health outcome attributable to 3,5-dimethoxytyramine in isolation.

7.2 Evidence for Mescaline-Containing Preparations (Context for the Whole-Plant Matrix)

Because 3,5-dimethoxytyramine occurs within the same botanical preparations as mescaline, evidence about peyote and related cacti as whole-plant preparations is contextually relevant — while acknowledging that any observed effects are predominantly attributable to mescaline and not to 3,5-dimethoxytyramine specifically.

Archaeological and ethnohistorical documentation of peyote use is extensive. Radiocarbon dating shows that the calibrated ¹⁴C age corresponds to the calendric time interval 3780–3660 BC. Alkaloid extraction yielded approximately 2% of alkaloids. Analysis with thin-layer chromatography (TLC) and gas chromatography-mass spectrometry (GC-MS) led to the identification of mescaline in both samples.

Mescaline pharmacokinetics and pharmacodynamics (human studies): A 2024 study published in the British Journal of Clinical Pharmacology conducted safety pharmacology assessment of acute mescaline administration in healthy participants. Mescaline was first isolated from peyote in 1896 and first synthesized in a laboratory in 1919. In psychiatry and neurology, mescaline was the first psychedelic that was used to mimic symptoms of schizophrenia and study its causes and possible treatments. In the early 1970s, psychedelics were banned, and research in humans decreased. Regarding metabolism, mescaline is mainly metabolized into trimethoxyphenylacetic acid by oxidative deamination, but several minor metabolites with possible clinical and forensic repercussions have also been reported.

Evidence strength for peyote/mescaline preparations: Human pharmacological data on mescaline has been accumulating since the mid-20th century, though controlled clinical trial data remains sparse. Most reports concerning mescaline were presented in a complete absence of exposure confirmation, since toxicological analysis is not widely available. Addiction and dependence are practically absent and it is clear that most intoxications appear to be mild and are unlikely to produce life-threatening symptoms, which favors the contemporary interest in the therapeutic potential of the drugs of the class. This evidence pertains to the whole-plant or mescaline-dominant preparations; the specific contribution of co-occurring 3,5-dimethoxytyramine cannot be disaggregated from these data.

7.3 Scaline Receptor Pharmacology (In Vitro, Most Relevant Structural Class)

A 2022 peer-reviewed study in Frontiers in Pharmacology (Kolaczynska et al.) examined the receptor interaction profiles of 4-alkoxy-3,5-dimethoxy-phenethylamines (scalines), which are direct structural relatives of 3,5-dimethoxytyramine. Several pharmacologically uninvestigated scalines and 3C-scalines were examined at key monoamine targets in vitro. Binding affinity at human serotonergic 5-HT₁A, 5-HT₂A, and 5-HT₂C, adrenergic α₁A and α₂A, and dopaminergic D₂ receptors, rat and mouse trace amine-associated receptor 1 (TAAR1), and human monoamine transporters were assessed using target-specific transfected cells. Furthermore, activation of human 5-HT₂A and 5-HT₂B receptors, and TAAR1 was examined. This in vitro evidence is relevant to the pharmacological class but does not directly characterize 3,5-dimethoxytyramine itself.

Evidence strength: In vitro, structural analogy only. No human data on isolated compound.

8. Body Systems and Health Areas of Association

The body systems and health areas with which 3,5-dimethoxytyramine is associated arise primarily from: (a) its role in the mescaline biosynthetic pathway and co-occurrence with pharmacologically active cactus alkaloids, (b) its enzymatic interactions within the catecholamine system, and (c) the broader pharmacology of its structural relatives.

Central Nervous System

The phenethylamine and scaline families, to which 3,5-dimethoxytyramine belongs, are strongly associated with central nervous system pharmacology. Mescaline, the structurally closest and most studied analogue, acts primarily on serotonin receptors in the brain. Mescaline interacts with the 5-HT₂A receptors in the brain, which pertain to how the body uses serotonin. These receptors are also the targets of other classic hallucinogens, such as LSD and psilocybin mushrooms. They are likely responsible for the "trip" a person experiences when using these substances. Whether 3,5-dimethoxytyramine produces any central effects in humans has not been investigated in controlled studies.

Catecholamine / Sympathetic Nervous System

Through its role as a substrate for dopamine-β-hydroxylase, 3,5-dimethoxytyramine is implicated in the enzymatic machinery of the catecholamine biosynthetic system. As a phenethylamine derivative, signs and symptoms [of related compounds] are consistent with a sympathomimetic effect. However, this characterization is based on the phenethylamine class broadly (and mescaline specifically), and has not been demonstrated specifically for 3,5-dimethoxytyramine in isolation in humans.

Traditional Medicine Associations (Peyote Complex)

Within the traditional medicine context of peyote use, the plant's alkaloid mixture (which includes 3,5-dimethoxytyramine) was applied to a wide range of conditions. Some of the illnesses treated with peyote by Mexican Natives are tuberculosis, pneumonia, scarlet fever, intestinal ills, diabetes, rheumatic pains, colds, grippe, fevers, and venereal diseases, which is why peyote is officially listed in the Mexican pharmacopoeia. These traditional applications apply to the whole-plant complex and cannot be attributed to 3,5-dimethoxytyramine specifically.

9. Dosage Forms and Reported Dosages

No peer-reviewed clinical or pharmacological studies have established a specific dosage, dose range, or dosage form for 3,5-dimethoxytyramine administered in isolation in humans. All dosage information in the literature pertains to:

• Whole peyote buttons: Dried peyote buttons are chewed, consumed as tea, or ground into powder for encapsulation. In traditional peyote preparations, the top of the cactus is cut at ground level, leaving the large tap roots to grow new "heads." These "heads" are then dried to make disc-shaped buttons, and the buttons are chewed to produce the effects or soaked in water to drink. In modern times, users will often grind it into a powder and pour it into gel capsules to avoid having to come into contact with the bitter taste of the cactus.
• Mescaline (the isolated major alkaloid): Mescaline is used recreationally, spiritually, and medically, with psychedelic effects occurring at doses from 100 to 1,000 mg and it can be used in pure crystalline form or via the crude extract of mescaline-containing cacti. The usual human dose is 200–400 milligrams of mescaline sulfate or 178–356 milligrams of mescaline hydrochloride. The average 76 mm button contains about 25 mg mescaline.

Because 3,5-dimethoxytyramine is a minor alkaloid within these preparations, its actual amount consumed in traditional or modern peyote use has not been quantified in the available peer-reviewed literature. No stand-alone supplement doses have been described in authoritative sources.

10. Safety Considerations and Interactions

No clinical safety data, adverse event reports, or interaction studies specific to isolated 3,5-dimethoxytyramine have been identified in peer-reviewed sources. Safety considerations must therefore be inferred from:

Class-Level Safety Considerations

Addiction and dependence are practically absent and it is clear that most intoxications appear to be mild and are unlikely to produce life-threatening symptoms. This assessment, from a comprehensive review of peyote and mescaline, applies to the whole-plant alkaloid complex and to mescaline specifically; it cannot be directly extended to 3,5-dimethoxytyramine in isolation.

As a phenethylamine derivative, 3,5-dimethoxytyramine carries the class-level consideration that such compounds may exert sympathomimetic effects. Its pharmacodynamic mechanisms of action [of the class] are primarily attributed to the interaction with the serotonergic 5-HT2A-C receptors. Moreover, as a phenethylamine derivative, signs and symptoms are consistent with a sympathomimetic effect.

Enzyme Substrate Interactions

3,5-Dimethoxytyramine has been identified as a substrate for dopamine-β-hydroxylase, which may be relevant in individuals with altered catecholamine metabolism or in situations of enzyme inhibition or induction. The enzyme dopamine-β-oxidase accepts as substrates a wide variety of phenethylamine derivatives, including 3,5-dimethoxytyramine. The significance of this for human safety in a supplemental context is unknown.

Monoamine Oxidase (MAO) Substrate Potential

Phenethylamines including tyramine and related compounds are well-established substrates for monoamine oxidase enzymes (MAO-A and MAO-B). Structural analogues of 3,5-dimethoxytyramine are metabolized by MAO, and individuals taking MAO inhibitors (MAOIs) — including certain antidepressants and some herbal preparations — may face heightened risk of adverse effects if exposed to phenethylamine-class compounds, due to impaired amine catabolism. This consideration applies by structural analogy; specific MAO substrate data for 3,5-dimethoxytyramine in isolation has not been confirmed in peer-reviewed human sources.

Regulatory Status

3,5-Dimethoxytyramine (4-O-Desmethylmescaline) does not appear on the United States Drug Enforcement Administration (DEA) Schedule of Controlled Substances as a specifically scheduled compound as of available records, though its close structural and botanical relationship to mescaline — which is a Schedule I controlled substance in the United States — may create legal ambiguity in some jurisdictions. The compound's status should be considered carefully in the context of applicable jurisdiction and analogue-act legislation.

11. Summary of Evidence Quality

3,5-Dimethoxytyramine is a minor naturally occurring cactus alkaloid and biosynthetic intermediate with no direct human clinical evidence base. The compound has been characterized chemically and identified analytically in multiple cactus species, including Lophophora williamsii (peyote), Echinopsis pachanoi (San Pedro), and related Cactaceae, as well as in certain Acacia species. Its role as a precursor and metabolite in the mescaline biosynthetic pathway is established. Its interaction as a substrate with mammalian dopamine-β-hydroxylase has been documented in early enzyme biochemistry literature. Structural analogy with the scaline family suggests plausible serotonergic receptor interactions, but these have not been confirmed for this specific compound in human pharmacological studies.

No clinical trials, controlled human studies, or systematic reviews examining 3,5-dimethoxytyramine as an isolated agent have been identified. Any characterization of its effects, efficacy, or safety in humans remains extrapolatory from (1) its co-occurrence within peyote preparations, (2) its structural relatedness to mescaline and the scaline series, and (3) its enzymatic interactions documented in preclinical research. The total body of direct evidence for this compound is preclinical, indirect, and preliminary.

References

• Wikipedia: 4-O-Desmethylmescaline (3,5-Dimethoxytyramine)
• Wikipedia: Peyote (Lophophora williamsii)
• Wikipedia: Mescaline
• Wikipedia: Echinopsis pachanoi (San Pedro Cactus)
• Wikipedia: Cactus Alkaloids
• Dinis-Oliveira RJ, Pereira Lança C, da Silva Dias D. Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions. Current Molecular Pharmacology. 2019;12(3). PMC6864602.
• Ibarra-Laclette E, et al. De novo sequencing and analysis of Lophophora williamsii transcriptome, and searching for putative genes involved in mescaline biosynthesis. BMC Genomics. 2015. PMC4557841.
• Watkins JL, et al. Elucidation of the mescaline biosynthetic pathway in peyote (Lophophora williamsii). The Plant Journal. 2023.
• El-Seedi HR, et al. Prehistoric peyote use: alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas. Journal of Ethnopharmacology. 2005;101(1–3):238–242.
• Creveling CR, Daly JW. Substrates and inhibitors of dopamine-β-oxidase. Biochemical Pharmacology. 1962.
• Kolaczynska KE, Luethi D, Trachsel D, Hoener MC, Liechti ME. Receptor interaction profiles of 4-alkoxy-3,5-dimethoxy-phenethylamines (mescaline derivatives) and related amphetamines. Frontiers in Pharmacology. 2022;12:794254.
• Cassels BK, Sáez-Briones P. The alkaloids from Lophophora diffusa and other "False Peyotes." Journal of Psychoactive Drugs. 2021.
• Klaiber A, et al. Safety pharmacology of acute mescaline administration in healthy participants. British Journal of Clinical Pharmacology. 2024.
• Pharmacokinetics, Pharmacodynamics, and Urinary Recovery of Oral Mescaline Hydrochloride in Healthy Participants. PMC12479620.